Givens Brittany E, Geary Sean M, Salem Aliasger K
Department of Chemical & Biochemical Engineering, College of Engineering, University of Iowa, Iowa City, IA, 52242, USA.
Division of Pharmaceutics & Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 52242, USA.
Immunotherapy. 2018 Jun;10(7):595-604. doi: 10.2217/imt-2017-0142. Epub 2018 Mar 23.
Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.
过敏性哮喘在发达国家正变得越来越普遍，许多常见过敏原能够诱发过敏性哮喘反应，尤其是在特应性个体中。未甲基化的CpG寡核苷酸（ODN）疗法可以改变免疫反应以减轻这些过敏反应。在临床前研究中，可溶性CpG-ODN的治疗性和预防性给药分别在治疗现有哮喘和预防随后接触过敏原时的过敏反应方面显示出前景。然而，当CpG-ODN与纳米颗粒偶联或自组装成纳米结构时，在临床前研究和临床试验中观察到CpG-ODN对几种常见过敏原的治疗效果有所提高。在此，我们讨论CpG-ODN在治疗过敏性哮喘中的作用以及基于纳米颗粒的递送如何进一步增强其治疗特性。
